Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease

22 Mar 2010

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hemoglobinopathies and Related Disorders
Share to Iron Metabolism and Disorders
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20305698
DOI: 10.1038/bmt.2010.60

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell diseasePMID 20305698Read ↗

Busulfan and Subsequent Malignancy: An Evidence-Based Risk AssessmentSemantic proximity Read ↗

Younger children with nonmalignant disease have increased incidence of mixed myeloid chimerism after allogeneic hematopoietic cell transplantation with busulfan-based conditioningSemantic proximity Read ↗

Update of hematopoietic cell transplantation for sickle cell diseaseSemantic proximity Read ↗

Curative approaches for sickle cell disease: A review of allogeneic and autologous strategiesSemantic proximity Read ↗

Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based conditioning prior to allogenic hematopoietic stem cell transplantation in children.Semantic proximity Read ↗

Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients.Semantic proximity Read ↗

Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is nowSemantic proximity Read ↗

Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell DiseaseSemantic proximity Read ↗

Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cellsSemantic proximity Read ↗

Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation.Semantic proximity Read ↗

Familial Haploidentical Stem Cell Transplant in Children and Adolescents With High-Risk Sickle Cell DiseaseSemantic proximity Read ↗

Role of Pharmacogenetics in Busulfan/Cyclophosphamide Conditioning Therapy Prior to Hematopoietic Stem Cell TransplantationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.